

## DAFTAR PUSTAKA

- Abate, B.B., Kassie, A.M., Kassaw, M.W., Aragie, T.G. & Masresha, S.A. 2020, 'Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis', *BMJ Open*, vol. 10, no. 10, pp. 1–10.
- Alwani, M., Yassin, A., Al-Zoubi, R.M., Aboumarzouk, O.M., Nettleship, J., Kelly, D., AL-Qudimat, A.R. & Shabsigh, R. 2021, 'Sex-based differences in severity and mortality in COVID-19', *Reviews in Medical Virology*, vol. 31, no. 6.
- Barek, Md.A., Aziz, Md.A. & Islam, M.S. 2020, 'Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases', *Heliyon*, vol. 6, no. 12.
- Biswas, M., Rahaman, S., Biswas, T.K., Haque, Z. & Ibrahim, B. 2021, 'Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis', *Intervirolgy*, vol. 64, no. 1, pp. 36–47.
- Burhan, E., Dwi Susanto, A., Isbaniah, F., Aman Nasution, S., Ginanjar, E., Wicaksono Pitoyo, C., Susilo, A., Firdaus, I., Santoso, A., Arifa Juzar, D., Kamsul Arif, S., Lolong Wulung, N.G., Muchtar, F., Pulungan, A.B., Ambara Sjakti, H., Prawira, Y. & Dwi, P. 2020, *Pedoman Tatalaksana COVID-19*, 3rd edn, PDPI PERKI PAPDI PERDATIN IDAI, Jakarta.
- Chen, Y., Klein, S.L., Garibaldi, B.T., Li, H., Wu, C., Osevala, N.M., Li, T., Margolick, J.B., Pawelec, G. & Leng, S.X. 2021, 'Aging in COVID-19: Vulnerability, immunity and intervention', *Ageing Research Reviews*, vol. 65, p. 101205.
- Chiba, S. 2021, 'Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19', *Wiener klinische Wochenschrift*, vol. 133, no. 7–8, pp. 292–7.
- Davies, B.E. 2010, 'Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations', *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 2, pp. 5–10.
- Dessie, Z.G. & Zewotir, T. 2021, 'Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients', *BMC Infectious Diseases*, vol. 21, no. 1, p. 855.
- Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., Abosalif, K.O.A., Ahmed, Z. & Younas, S. 2020, 'COVID-19 and comorbidities: Deleterious impact on infected patients', *Journal of Infection and Public Health*, vol. 13, no. 12, pp. 1833–9.

- Fang, X., Li, S., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H. & Ma, X. 2020, 'Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis', *Aging*, vol. 12, no. 13, pp. 12493–503.
- Galbadage, T., Peterson, B.M., Awada, J., Buck, A.S., Ramirez, D.A., Wilson, J. & Gunasekera, R.S. 2020, 'Systematic Review and Meta-Analysis of Sex-Specific COVID-19 Clinical Outcomes', *Frontiers in Medicine*, vol. 7, no. 348.
- Jackson, C.B., Farzan, M., Chen, B. & Choe, H. 2022, 'Mechanisms of SARS-CoV-2 entry into cells', *Nature Review Molecular Cell Biology*, vol. 23, no. 1, pp. 3–20, viewed 13 September 2022, <[www.nature.com/nrm](http://www.nature.com/nrm)>.
- Ji, Y.L., Wu, Y., Qiu, Z., Ming, H., Zhang, Y., Zhang, A.N., Leng, Y. & Xia, Z.Y. 2021, 'The Pathogenesis and Treatment of COVID-19: A System Review', *Biomedical and Environmental Sciences*, Elsevier Ltd, pp. 50–60.
- Kirtipal, N., Bharadwaj, S. & Kang, S.G. 2020, 'From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses', *Infection, Genetics, and Evolution*, vol. 85, no. 2020, p. 104502.
- Laborda, P., Wang, S.-Y. & Voglmeir, J. 2016, 'Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity', *Molecules*, vol. 21, no. 11, p. 1513.
- Lin, S.-N., Rui, J., Chen, Q.-P., Zhao, B., Yu, S.-S., Li, Z.-Y., Zhao, Z.-Y., Wang, Y., Zhu, Y.-Z., Xu, J.-W., Yang, M., Liu, X.-C., Yang, T.-L., Luo, L., Deng, B., Huang, J.-F., Liu, C., Li, P.-H., Liu, W.-K., Xie, F., Chen, Y., Su, Y.-H., Zhao, B.-H., Chiang, Y.-C. & Chen, T.-M. 2021, 'Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study', *Infectious Diseases of Poverty*, vol. 10, no. 1, p. 53.
- Majumder, J. & Minko, T. 2021, 'Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19', *The AAPS Journal*, vol. 23, no. 1, p. 14.
- Mamidala, E., Davella, R., Gurrupu, S. & Shivakrishna, P. 2022, 'In Silico Identification of Clinically Approved Medicines Against the main Protease of Sars-Cov-2 – A Causative Agent of Covid-19', *International Journal of Life Science and Pharma Research*.
- McKimm-Breschkin, J.L. 2013, 'Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance', *Influenza and Other Respiratory Viruses*, vol. 7, pp. 25–36.

- Ng, W.H., Tipih, T., Makoah, N.A., Vermeulen, J.-G., Goedhals, D., Sempa, J.B., Burt, F.J., Taylor, A. & Mahalingam, S. 2021, 'Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis', *mBio*, vol. 12, no. 1.
- Ochani, R.K., Asad, A., Yasmin, F., Shaikh, S., Khalid, H., Batra, S., Sohail, M.R., Mahmood, S.F., Ochani, R., Arshad, M.H., Kumar, A. & Surani, S. 2021, 'COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management', *Infez Med*, vol. 29, no. 1, pp. 20–6.
- Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M.H., Sarraf, P. & Djalali, M. 2020, 'Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies', *The Aging Male*, vol. 23, no. 5, pp. 1416–24.
- Rahman, S., Teresa, M., Montero, V., Rowe, K., Kirton, R. & Kunik, F. 2021, 'Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence', *Expert Review of Clinical Pharmacology*, vol. 14, no. 5, pp. 601–21.
- Rashedi, J., Poor, B.M., Asgharzadeh, V., Pourostadi, M., Kafil, H.S., Vegari, A., Tayebi-khosroshahi, H. & Asgharzadeh, M. 2020, 'Risk Factor for COVID-19', *Le Infezioni in Medicina*, vol. 4, pp. 469–74.
- Sanders, J.M., Monogue, M.L., Jodlowski, T.Z. & Cutrell, J.B. 2020, 'Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)', *JAMA*.
- Schultze, J.L. & Aschenbrenner, A.C. 2021, 'COVID-19 and the human innate immune system', *Cell*, Elsevier B.V., pp. 1671–92.
- Tan, Q., Duan, L., Ma, Y., Wu, F., Huang, Q., Mao, K., Xiao, W., Xia, H., Zhang, S., Zhou, E., Ma, P., Song, S., Li, Y., Zhao, Z., Sun, Y., Li, Z., Geng, W., Yin, Z. & Jin, Y. 2020, 'Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study', *Bioorganic Chemistry*, vol. 104, p. 104257.
- Yesudhas, D., Srivastava, A. & Gromiha, M.M. 2021, 'COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics', *Infection*, Springer Science and Business Media Deutschland GmbH, pp. 199–213.
- Yousefi, H., Mashouri, L., Okpechi, S.C., Alahari, N. & Alahari, S.K. 2021, 'Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action', *Biochemical Pharmacology*, vol. 183, p. 114296.

- Zendehdel, A., Bidkhor, M., Ansari, M., Jamalimoghaddamsiyahkali, S. & Asoodeh, A. 2022, 'Efficacy of oseltamivir in the treatment of patients infected with Covid-19', *Annals of Medicine and Surgery*, vol. 77, p. 103679.
- Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., Ye, C., Zhang, P., Xing, Y., Guo, H. & Tang, W. 2020, 'Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis', *Journal of Infection*, W.B. Saunders Ltd, pp. 16–25.

